TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28929698

Group type: EXPERIMENTAL
Intervention: S. flavescens gel (test group, 40 cases)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Human recombinant interferon α‐2b gel (control group, 40 cases)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of S. flavescens gel and human recombinant interferon α‐2b gel (combined application group, 40 cases)
Number of subjects: 120
Study: 25163441

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol (mean peak blood alcohol content of 0.051%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol/energy drink
Number of subjects: 24

Group type: COMPARATOR
Intervention: Energy drink alone (250 ml)
Number of subjects: 24
Study: 23032549

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (200,000 IU initial dose, 200,000 IU one month later, then 100,000 IU monthly for 18 months)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo (identical dosing regimen to vitamin D3)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 20656473

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 169
Study: 17557356

Group type: EXPERIMENTAL
Intervention: Dopaminergic treatment (ON state)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Nonmedicated PD (OFF state)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Healthy participants (Control)
Number of subjects: 73
Study: 16787687

Group type: COMPARATOR
Intervention: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC)
Number of subjects: 926

Group type: COMPARATOR
Intervention: docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb)
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC)
Number of subjects: 926
Study: 12066419

Group type: EXPERIMENTAL
Intervention: Morphemic priming observed after identifying the colour of a single letter in the prime display.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic priming observed after identifying the colour of a single letter in the prime display.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identifying the colour of a single letter in the Stroop task.
Number of subjects: 0
Study: 10692755

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 26
Study: 9127183

Group type: EXPERIMENTAL
Intervention: Outpatient continence program
Number of subjects: 74

Group type: COMPARATOR
Intervention: Inpatient continence program
Number of subjects: 74
Study: 1863429

Group type: EXPERIMENTAL
Intervention: 500 ppm fluoride mouthrinse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 0
Study: 6129458

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LM 24056
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poldine
Number of subjects: 0
Study: 29584516

Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia Training (IHT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 28351962

Group type: EXPERIMENTAL
Intervention: Gly49 allele carriers
Number of subjects: 926

Group type: COMPARATOR
Intervention: Ser49Ser genotype
Number of subjects: 926
Study: 25982720

Group type: EXPERIMENTAL
Intervention: ICD implantation based on trial data
Number of subjects: 150264

Group type: EXPERIMENTAL
Intervention: Age-related criteria
Number of subjects: 150264

Group type: EXPERIMENTAL
Intervention: Prior cardiac transplantation
Number of subjects: 150264

Group type: EXPERIMENTAL
Intervention: Pediatric electrophysiology operator
Number of subjects: 150264

Group type: EXPERIMENTAL
Intervention: High-grade atrioventricular conduction disease
Number of subjects: 150264
Study: 23336294

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg once daily started 6-8 hours after surgery)
Number of subjects: 12576

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 12576

Group type: EXPERIMENTAL
Intervention: Both rivaroxaban and enoxaparin
Number of subjects: 12576
Study: 21232874

Group type: EXPERIMENTAL
Intervention: Cortisol (0.1mg/kg body weight)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19597277

Group type: EXPERIMENTAL
Intervention: Lidocaine-PTC
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17023076

Group type: EXPERIMENTAL
Intervention: Fit program (physical training plus information about their disease for 6 weeks)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Fit-Plus program (comprehensive cardiac rehabilitation including Fit program plus weekly psycho-education sessions and relaxation therapy for 8 weeks)
Number of subjects: 137
Study: 15181655

Group type: EXPERIMENTAL
Intervention: Olanzapine (administered for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Risperidone (maintained without change in daily dose)
Number of subjects: 28
Study: 12162596

Group type: EXPERIMENTAL
Intervention: Potassium aspartate (2 vials K-Flebo d(‐1) = 60 mEq d(‐1), per os)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No potassium supplementation (control group)
Number of subjects: 28
Study: 9710030

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (500 mg once a day for 5 days with a 10-day tapering period)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7802244

Group type: EXPERIMENTAL
Intervention: Direct-puncture technique (method A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Catheter with a separate guide wire (method B)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Catheter with an integral guide wire (method C)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Catheter types B and C (polyurethane)
Number of subjects: 69
Study: 2920502

Group type: EXPERIMENTAL
Intervention: WEB 2086 (three times 40 mg/day) for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WEB 2086 (three times 100 mg/day) for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 5732492

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Ball-pulling (reinforcement schedule)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Free reinforcer delivery
Number of subjects: 1
Study: 30169658

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) experienced in the past year
Number of subjects: 3496

Group type: EXPERIMENTAL
Intervention: Intimate partner violence (IPV) experienced as both a victim and perpetrator
Number of subjects: 3496
Study: 28323838

Group type: EXPERIMENTAL
Intervention: Bupropion 150/300mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25186785

Group type: EXPERIMENTAL
Intervention: Pill count adherence
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Detectable drug concentrations
Number of subjects: 1219
Study: 24112970

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 292
Study: 21133642

Group type: EXPERIMENTAL
Intervention: Total tonsillectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (age-matched children)
Number of subjects: 67
Study: 19482235

Group type: EXPERIMENTAL
Intervention: Cortisone 25mg orally before stress test
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17376563

Group type: EXPERIMENTAL
Intervention: Simulation based teaching (SBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lecture based teaching (LBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combination of lecture and simulation (LAS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SBT
Number of subjects: 36
Study: 15538132

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amphetamine (30 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11172153

Group type: EXPERIMENTAL
Intervention: Cerebral edema group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bicarbonate treatment
Number of subjects: 61
Study: 9550459

Group type: EXPERIMENTAL
Intervention: Nasoenteral tube feedings at 125 cc/hour over 11 hours each night in addition to standard post-operative nutritional care
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard post-operative care
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nasoenteral tube feedings
Number of subjects: 18
Study: 7839535

Group type: EXPERIMENTAL
Intervention: Nicotine treatment
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 289
Study: 2541121

Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum (150 mg/m2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum (120 mg/m2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum (cumulative dose of 725 mg/m2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: WR-2721 and cis-platinum
Number of subjects: 118
Study: 6402

Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 1.0%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution 1.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution (all concentrations)
Number of subjects: 0
Study: 31175364

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive patients
Number of subjects: 250

Group type: COMPARATOR
Intervention: Barrett's esophagus patients
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Presence of erosive esophagitis, length of BE, or dysplasia
Number of subjects: 250
Study: 27659121

Group type: EXPERIMENTAL
Intervention: Version 1 of SBD measures
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Version 2 of SBD measures
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Version 3 of SBD measures
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Group 5 (specific version of SBD measures)
Number of subjects: 781

Group type: COMPARATOR
Intervention: All versions of SBD measures
Number of subjects: 781
Study: 25962601

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and adalimumab (DMARD+ADA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Methotrexate (MTX) and placebo (DMARD+PLA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Withdrawal of adalimumab (ADA) after 12 months of treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Baseline sCD163
Number of subjects: 150
Study: 23782672

Group type: EXPERIMENTAL
Intervention: Depression Medication Choice decision aid
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual depression care
Number of subjects: 300
Study: 21544671

Group type: EXPERIMENTAL
Intervention: Internet-based survivorship care program
Number of subjects: 775
Study: 19811180

Group type: EXPERIMENTAL
Intervention: Web-based learning (WBL)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Face-to-face problem-based learning (PBL)
Number of subjects: 148
Study: 17855815

Group type: EXPERIMENTAL
Intervention: Early hemodynamic optimization strategies (early goal-directed therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 14713799

Group type: EXPERIMENTAL
Intervention: Extended release ciprofloxacin 1,000 mg once daily
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Conventional ciprofloxacin 500 mg twice daily
Number of subjects: 1035
Study: 10708840

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Imipramine (IMN)
Number of subjects: 45
Study: 8632216

Group type: EXPERIMENTAL
Intervention: High dose vitamin A supplements
Number of subjects: 1407
Study: 1575179

Group type: EXPERIMENTAL
Intervention: Duteplase (rt-PA) maintenance infusion at doses of 0.012, 0.024, 0.036, 0.048 MIU/kg/hour for 9 to 21 hours
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Total dose of rt-PA administered
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Factors associated with serious bleeding
Number of subjects: 213
Study: 6370150

Group type: EXPERIMENTAL
Intervention: Chloroquine 250 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dapsone 100 mg daily (50 mg/day for the first 7 days)
Number of subjects: 60
Study: 31444929

Group type: EXPERIMENTAL
Intervention: Treadmill training (TreSPE) in addition to stretching and proprioceptive exercise
Number of subjects: 53

Group type: COMPARATOR
Intervention: Stretching and proprioceptive exercise
Number of subjects: 53
Study: 31126337

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychological therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAD-7 questionnaire score of at least 10
Number of subjects: 0
Study: 29979888

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Interactive nutrition education approaches
Number of subjects: 665
Study: 26824595

Group type: EXPERIMENTAL
Intervention: Acetazolamide administration for 10 days
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Prone positioning for 10 days
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Acetazolamide administration and prone positioning for 10 days
Number of subjects: 161

Group type: COMPARATOR
Intervention: No intervention (Control Group D)
Number of subjects: 161
Study: 24806383

Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) add-on group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional diuretics group
Number of subjects: 100
Study: 22032303

Group type: EXPERIMENTAL
Intervention: Lupin protein + cellulose
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Pea protein + cellulose
Number of subjects: 175

Group type: COMPARATOR
Intervention: Casein + cellulose
Number of subjects: 175

Group type: COMPARATOR
Intervention: Casein + oat fibre
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Pea protein + oat fibre
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Casein + apple pectin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Pea protein + apple pectin
Number of subjects: 175
Study: 19852294

Group type: EXPERIMENTAL
Intervention: C‐QBO
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: F‐QBO
Number of subjects: 93

Group type: COMPARATOR
Intervention: White Vaseline (Control)
Number of subjects: 93
Study: 17515264

Group type: EXPERIMENTAL
Intervention: Kliniplot mattress
Number of subjects: 1729

Group type: COMPARATOR
Intervention: Standard hospital mattress
Number of subjects: 1729
Study: 14742990

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Sirolimus (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Mycophenolate Mofetil (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine (Neoral)/Sirolimus (Group C)
Number of subjects: 0
Study: 12352037

Group type: EXPERIMENTAL
Intervention: Supplemented parenteral nutrition with l‐alanyl‐l‐glutamine (0.3 g.kg.body weight per day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard parenteral nutrition
Number of subjects: 144
Study: 9839522

Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination (DRE)
Number of subjects: 10523

Group type: EXPERIMENTAL
Intervention: DRE in conjunction with serum PSA measurement and TRUS
Number of subjects: 10523

Group type: EXPERIMENTAL
Intervention: DRE
Number of subjects: 10523
Study: 7915442

Group type: EXPERIMENTAL
Intervention: cM‐T412 (chimeric CD4 monoclonal antibody)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (antithymocyte globulin until cyclosporine in serum reached therapeutic levels)
Number of subjects: 11
Study: 2655367

Group type: EXPERIMENTAL
Intervention: Modification of intravenous regional analgesia technique (removal of excess local anaesthetic solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of local anaesthetic agent removed from the isolated arm after 15 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removal of excess local anaesthetic agent after 15 min
Number of subjects: 0
Study: 1108754

Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg capsules, optimal daily dose ranged from two to seven capsules.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Loperamide 2 mg capsules (in double-blind placebo-controlled trial for ten days or until relapse).
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg capsules.
Number of subjects: 15
Study: 31402400

Group type: EXPERIMENTAL
Intervention: Head-out immersion in natural thermal mineral water (HINTMW) alone
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Head-out immersion in natural thermal mineral water (HINTMW) as an adjuvant therapy to medication
Number of subjects: 1122

Group type: EXPERIMENTAL
Intervention: Head-out immersion in natural thermal mineral water (HINTMW) combined with other interventions (natural convalescent factor therapy, psychotherapy, exercises, nutrition therapy, integrated care)
Number of subjects: 1122

Group type: COMPARATOR
Intervention: Basic antihypertensive drugs
Number of subjects: 1122
Study: 28722611

Group type: EXPERIMENTAL
Intervention: Ferroquine + Artesunate (200 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Amodiaquine (612 mg/day) + Artesunate (200 mg/day)
Number of subjects: 72
Study: 25928545

Group type: EXPERIMENTAL
Intervention: Daily iron-folic acid (IFA)
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Twice-weekly iron-folic acid (IFA)
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Micronutrients (MMN)
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Usual antenatal care (OS)
Number of subjects: 1258
Study: 23816766

Group type: EXPERIMENTAL
Intervention: Magnesium pretreatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 40
Study: 22292247

Group type: EXPERIMENTAL
Intervention: Basic family planning/HIV integration model
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Enhanced family planning/HIV integration model
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: ART providers' family planning counseling
Number of subjects: 274
Study: 18562447

Group type: EXPERIMENTAL
Intervention: Software application for managing hyperbilirubinaemia
Number of subjects: 15

Group type: COMPARATOR
Intervention: Manual application of AAP guidelines
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Software application
Number of subjects: 15
Study: 16924799

Group type: EXPERIMENTAL
Intervention: SCENAR therapy
Number of subjects: 103
Study: 15180356

Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fexofenadine (120 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12903420

Group type: EXPERIMENTAL
Intervention: Alanyl‐glutamine [0.5 g/(kg.d)]
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (isocaloric parenteral nutrition without glutamine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 9350072

Group type: EXPERIMENTAL
Intervention: Metformin up to 2000 mg day-1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 60
Study: 1440126

Group type: EXPERIMENTAL
Intervention: Foam brush
Number of subjects: 29

Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 29
Study: 3826915

Group type: EXPERIMENTAL
Intervention: Serum phenobarbital measurements
Number of subjects: 70
Study: 31698478

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.035 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 6
Study: 29856175

Group type: EXPERIMENTAL
Intervention: Blueberry juice (500 mL/day for 14 days preoperatively)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no blueberry juice)
Number of subjects: 26
Study: 26989182

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 26586322

Group type: EXPERIMENTAL
Intervention: 4-week group psychotherapy intervention facilitated by a clinical psychologist
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 22987106

Group type: EXPERIMENTAL
Intervention: JET group
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 20682457

Group type: EXPERIMENTAL
Intervention: Practical group counseling (PGC) psychotherapy (n=14)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bupropion HCl (n=14)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Matching pill placebo (n=15)
Number of subjects: 43
Study: 18184396

Group type: EXPERIMENTAL
Intervention: Commercial weight loss programmes (specific diets not detailed)
Number of subjects: 0
Study: 17199952

Group type: COMPARATOR
Intervention: Amiodarone 200 mg daily (Group A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Amiodarone 100 mg daily (Group B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 76
Study: 14618939

Group type: EXPERIMENTAL
Intervention: DEAE-Dextran at 2.5 g/day
Number of subjects: 202

Group type: COMPARATOR
Intervention: Cholestyramine at 12 g/day
Number of subjects: 202
Study: 10403579

Group type: EXPERIMENTAL
Intervention: n-3 PUFA enriched diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 6
Study: 7627695

Group type: EXPERIMENTAL
Intervention: Probucol (0.5 g BID) added to diet and cholestyramine (8 g BID)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Probucol (0.5 g BID)
Number of subjects: 303
Study: 2035782

Group type: EXPERIMENTAL
Intervention: Topical 1% amethocaine hydrochloride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study: 6119942

Group type: EXPERIMENTAL
Intervention: Azonutril 25
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Totamine Concentré Glucidic
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vamine
Number of subjects: 120